Advanced Inhalation Therapies (AIT Ltd.) announced that it has begun enrollment in Israel for a multicenter, open label, Phase II clinical trial of NOxCureCF, a respiratory treatment for patients with cystic fibrosis (CF). NOxCureCF is a specialized formulation of inhaled Nitric Oxide (NO) delivered using AIT's patented drug delivery system. CF is a life-threatening genetic disease that causes the abnormal transport of salts across cells and most critically affects the lungs.

CF patients are highly prone to opportunistic bacterial infections that often lead to prolonged, chronic lung infections, reducing life expectancy due to significant destruction of lung tissue. Approximately 70,000 individuals in Europe and North America suffer from CF, making it the most common life-threatening autosomal recessive disease. The aim of the study is to assess the improvement in lung function after treatment with NOxCureCF in CF patients 10 years old and older.

The study will also allow continuous testing of the safety and tolerability of the dosage and delivery system.